Kaken Pharmaceutical Co., Ltd.
Mitsubishi Tanabe Pharma Corporation
November 8, 2017 – Kaken Pharmaceutical Co., Ltd. (“Kaken”, head office Bunkyo-ku, Tokyo; President and Representative Director Tetsuo Onuma) and Tai Tien Pharmaceuticals Co., Ltd. (“Tai Tien”, head office Taipei, Taiwan; General Manager Hitoshi Kawabe), which is a consolidated subsidiary of Mitsubishi Tanabe Pharma Corporation (head office Chuo-ku, Osaka; President and Representative Director Masayuki Mitsuka), announced today that Kaken and Tai Tien concluded an exclusive distribution agreement for the topical formulation for Onychomycosis “Clenafin / Jublia” (“Product” ) in Taiwan.
The Product contains efinaconazole, which is new triazole anti-fungal compound discovered by Kaken, as the active ingredient. Efinaconazole has low binding affinity with keratin, the main component of nails, meaning that the Product has superior nail-penetrating properties.
The Product was launched under the trade name of Clenafin in Japan by Kaken in 2014. Overseas, the Product was launched under the trade name of Jublia, in the United States and Canada by Valeant Pharmaceutical International, Inc. in 2014 and in Korea by Dong-A ST Co., Ltd. in 2017.
According to the agreement, Kaken hereby grants to Tai Tien the exclusive right for sales of the Product in Taiwan. Tai Tien expects to launch the Product in 2018.
About Tai Tien
Tai Tien, which was established in 1987, has marketed a lot of products in the area of dermatology in Taiwan. Based on its sales performance and experience in such area, Tai Tien will try to quick spread of the Product into the Taiwanese market.
For further information, please contact: